Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 61.8% in March

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 56,800 shares, an increase of 61.8% from the February 28th total of 35,100 shares. Currently, 0.2% of the company's shares are sold short. Based on an average daily volume of 210,800 shares, the days-to-cover ratio is currently 0.3 days.

Kamada Price Performance

KMDA traded up $0.01 on Wednesday, reaching $6.71. The company's stock had a trading volume of 47,990 shares, compared to its average volume of 79,802. The business's 50 day moving average is $7.13 and its 200 day moving average is $6.34. Kamada has a 1 year low of $4.74 and a 1 year high of $9.16. The stock has a market cap of $385.69 million, a price-to-earnings ratio of 23.96, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Kamada Announces Dividend

The firm also recently declared a -- dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.20 per share. The ex-dividend date is Monday, March 17th.

Hedge Funds Weigh In On Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Geode Capital Management LLC increased its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the period. Aristides Capital LLC lifted its stake in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after acquiring an additional 6,850 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after acquiring an additional 8,260 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Kamada during the fourth quarter valued at approximately $67,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Kamada during the third quarter worth approximately $77,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KMDA has been the topic of a number of research analyst reports. Benchmark assumed coverage on Kamada in a report on Friday, March 21st. They issued a "buy" rating and a $15.00 target price on the stock. StockNews.com downgraded Kamada from a "strong-buy" rating to a "buy" rating in a report on Tuesday, March 25th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.